06/07/22 8:41 AMNasdaq : BVXV clinical trialcovid-19low floatBiondVax receives supportive Scientific Advice from the Paul Ehrlich Institute (PEI) for COVID-19 NanoAb development plans including first-in-human Phase 1/2a safety and efficacy clinical trialPEI supports BiondVax's plan for first-in-human clinical trial to be conducted in patients as a combined Phase 1/2a, testing both safety and efficacy, thereby shortening BiondVax's clinical development timelines for its first NanoAb product, a COVID-19 therapeutic; PEI is a part of the GermanRHEA-AIvery positive
06/01/22 7:10 AMNasdaq : BVXV earningslow floatBiondVax Announces First Quarter 2022 Financial Results and Provides Business UpdateBiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceuticals company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today published its firstRHEA-AIvery positive
05/19/22 11:17 AMNasdaq : BVXV conferenceslow floatBiondVax to Present at H.C. Wainwright Global Investment ConferenceBiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced that it willRHEA-AIneutral
05/12/22 6:30 AMNasdaq : BVXV low floatBiondVax Provides Update at Biomed Israel Conference and Announces Significant Progress in its Nanosized Antibodies ProgramBiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, announced that Dr. TamarRHEA-AIvery positive
05/09/22 6:00 AMNasdaq : BVXV conferenceslow floatBiondVax to Present at this week's Biomed Israel ConferenceBiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced that it willRHEA-AIneutral
04/05/22 6:49 AMNasdaq : BVXV conferenceslow floatBiondVax to host a Hebrew-language analyst and investor webinar on April 6thBiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, announced today that theRHEA-AIneutral
03/31/22 4:00 PMNasdaq : BVXV conferenceslow floatBiondVax to host analyst and investor webinar on April 4thBiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, announced today that theRHEA-AIneutral
03/28/22 7:00 AMNasdaq : BVXV earningslow floatBiondVax Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business UpdateBiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today published its fourthRHEA-AIvery positive
03/24/22 7:05 AMNasdaq : BVXV low floatBiondVax signs definitive collaboration agreement for the development of a pipeline of innovative nanosized antibody (NanoAb) therapiesBiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced the signingRHEA-AIvery positive
03/14/22 8:31 AMNasdaq : BVXV low floatEuropean Investment Bank Agrees in Principle to Extend the Maturity of its Loan until December 2027 with Additional Terms that Provide Continued Long-Term Support for BiondVax's New StrategyBiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced today that it had been negotiating with the European Investment Bank (the "EIB") terms of restructuring of its outstanding €24 million loan (the "Loan"). The parties have reached a commercialRHEA-AIpositive